Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
New member
Sign up for FREE
New customer
Discover our services
Settings
Settings
Dynamic quotes 
OFFON

MarketScreener Homepage  >  Equities  >  Xetra  >  Evotec SE    EVT   DE0005664809

EVOTEC SE

(EVT)
  Report
SummaryQuotesChartsNewsCalendarCompanyFinancialsConsensusRevisions 
SummaryMost relevantAll NewsPress ReleasesOfficial PublicationsSector newsMarketScreener StrategiesAnalyst Recommendations

Evotec SE: Release according to Article 40, Section 1 of the WpHG [the German Securities Trading Act] with the objective of Europe-wide distribution

10/27/2020 | 12:49pm EST

DGAP Voting Rights Announcement: Evotec SE
Evotec SE: Release according to Article 40, Section 1 of the WpHG [the German Securities Trading Act] with the objective of Europe-wide distribution

27.10.2020 / 18:49
Dissemination of a Voting Rights Announcement transmitted by DGAP - a service of EQS Group AG.
The issuer is solely responsible for the content of this announcement.


Notification of Major Holdings

1. Details of issuer
Name: Evotec SE
Street: Manfred Eigen Campus / Essener Bogen 7
Postal code: 22419
City: Hamburg
Germany
Legal Entity Identifier (LEI): 529900F9KI6OYITO9B12

2. Reason for notification
  Acquisition/disposal of shares with voting rights
  Acquisition/disposal of instruments
  Change of breakdown of voting rights
X Other reason:
Voluntary group notification with threshold triggered at subsidiary level due to exercise of instruments

3. Details of person subject to the notification obligation
Legal entity: Morgan Stanley
City of registered office, country: Wilmington, Delaware, United States of America (USA)

4. Names of shareholder(s)
holding directly 3% or more voting rights, if different from 3.
 

5. Date on which threshold was crossed or reached:
20 Oct 2020

6. Total positions
  % of voting rights attached to shares
(total of 7.a.)
% of voting rights through instruments
(total of 7.b.1 + 7.b.2)
Total of both in %
(7.a. + 7.b.)
Total number of voting rights pursuant to Sec. 41 WpHG
New 0.29 % 13.07 % 13.35 % 163494444
Previous notification 0.02 % 14.48 % 14.50 % /

7. Details on total positions
a. Voting rights attached to shares (Sec. 33, 34 WpHG)
ISIN Absolute In %
  Direct
(Sec. 33 WpHG)
Indirect
(Sec. 34 WpHG)
Direct
(Sec. 33 WpHG)
Indirect
(Sec. 34 WpHG)
DE0005664809 0 468078 0.00 % 0.29 %
Total 468078 0.29 %

b.1. Instruments according to Sec. 38 (1) no. 1 WpHG
Type of instrument Expiration or maturity date Exercise or conversion period Voting rights absolute Voting rights in %
Call Option From 18.12.2020 to 19.03.2021 at any time 76000 0.05 %
Right of recall over securities lending agreements at any time at any time 19879327 12.16 %
    Total 19955327 12.21 %

b.2. Instruments according to Sec. 38 (1) no. 2 WpHG
Type of instrument Expiration or maturity date Exercise or conversion period Cash or physical settlement Voting rights absolute Voting rights in %
Retail Structured Product From 10.01.2069 to 24.07.2070 at any time Cash 43654 0.03 %
Equity Swap From 07.06.2021 to 13.09.2024 at any time Cash 1363280 0.83 %
      Total 1406934 0.86 %

8. Information in relation to the person subject to the notification obligation
  Person subject to the notification obligation is not controlled nor does it control any other undertaking(s) that directly or indirectly hold(s) an interest in the (underlying) issuer (1.).
X Full chain of controlled undertakings starting with the ultimate controlling natural person or legal entity:

Name % of voting rights (if at least 3% or more) % of voting rights through instruments (if at least 5% or more) Total of both (if at least 5% or more)
Morgan Stanley % % %
Morgan Stanley Capital Management, LLC % % %
Morgan Stanley Domestic Holdings, Inc. % % %
Morgan Stanley Capital Services LLC % % %
- % % %
Morgan Stanley % % %
Morgan Stanley Capital Management, LLC % % %
Morgan Stanley Domestic Holdings, Inc. % % %
Morgan Stanley & Co. LLC % 7.02 % 7.15 %
- % % %
Morgan Stanley % % %
Morgan Stanley International Holdings Inc. % % %
Morgan Stanley International Limited % % %
Morgan Stanley Investments (UK) % % %
Morgan Stanley & Co. International plc % % 5.03 %
- % % %
Morgan Stanley % % %
Morgan Stanley Capital Management, LLC % % %
Morgan Stanley Domestic Holdings, Inc. % % %
Morgan Stanley & Co. LLC % % %
Prime Dealer Services Corp. % % %
- % % %
Morgan Stanley % % %
Morgan Stanley Capital Management, LLC % % %
Morgan Stanley Domestic Holdings, Inc. % % %
Morgan Stanley Smith Barney LLC % % %
- % % %
Morgan Stanley % % %
Morgan Stanley International Holdings Inc. % % %
Morgan Stanley International Limited % % %
Morgan Stanley Europe Holding SE % % %
Morgan Stanley Europe SE % % %
- % % %
Morgan Stanley % % %
E*TRADE Financial, LLC % % %
ETCM Holdings, LLC % % %
E*TRADE Securities LLC % % %

9. In case of proxy voting according to Sec. 34 para. 3 WpHG
(only in case of attribution of voting rights in accordance with Sec. 34 para. 1 sent. 1 No. 6 WpHG)

Date of general meeting:
Holding total positions after general meeting (6.) after annual general meeting:
Proportion of voting rights Proportion of instruments Total of both
% % %

10. Other explanatory remarks:
Please note that the reason for notification selected relates to the specific activity which occurred on the Date on which threshold was crossed or reached and which contributed to the triggering of the notification obligation and therefore may not also correspond to the comparison of New & Previous notification % values in the Total Positions section. 

Date
26 Oct 2020



27.10.2020 The DGAP Distribution Services include Regulatory Announcements, Financial/Corporate News and Press Releases.
Archive at www.dgap.de


Language: English
Company: Evotec SE
Manfred Eigen Campus / Essener Bogen 7
22419 Hamburg
Germany
Internet: www.evotec.com

 
End of News DGAP News Service

1143296  27.10.2020 

fncls.ssp?fn=show_t_gif&application_id=1143296&application_name=news&site_id=zonebourse_sftp

© EQS 2020
All news about EVOTEC SE
11/25EVOTEC : and Rappta Therapeutics enter discovery and development partnership foc..
AQ
11/24EVOTEC : And rappta therapeutics enter discovery and development partnership foc..
EQ
11/20EVOTEC : presents growth drivers of 'Autobahn to Cures' at Capital Markets Day
AQ
11/20EVOTEC : Gets a Buy rating from RBC
MD
11/19EVOTEC : Presents growth drivers of 'autobahn to cures' at capital markets day
EQ
11/18EVOTEC : and STORM Therapeutics leverage INDiGO platform to progress oncology pr..
AQ
11/17EVOTEC : and STORM Therapeutics leverage INDiGO platform to progress oncology pr..
PU
11/17EVOTEC : And storm therapeutics leverage indigo platform to progress oncology pr..
EQ
11/16EVOTEC SE : Notification and public disclosure of transactions by persons
EQ
11/13EVOTEC : Deutsche Bank reiterates its Buy rating
MD
More news
Financials
Sales 2020 475 M 568 M 568 M
Net income 2020 26,4 M 31,6 M 31,6 M
Net cash 2020 7,50 M 8,97 M 8,97 M
P/E ratio 2020 180x
Yield 2020 -
Capitalization 4 202 M 5 024 M 5 027 M
EV / Sales 2020 8,83x
EV / Sales 2021 7,53x
Nbr of Employees 3 444
Free-Float 90,7%
Chart EVOTEC SE
Duration : Period :
Evotec SE Technical Analysis Chart | MarketScreener
Full-screen chart
Technical analysis trends EVOTEC SE
Short TermMid-TermLong Term
TrendsBullishBullishNeutral
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus BUY
Number of Analysts 9
Average target price 30,67 €
Last Close Price 25,74 €
Spread / Highest target 39,9%
Spread / Average Target 19,1%
Spread / Lowest Target 8,78%
EPS Revisions
Managers
NameTitle
Werner Lanthaler Chief Executive Officer
Wolfgang Plischke Chairman-Supervisory Board
Craig L. Johnstone Chief Operating Officer & Member-Management Board
Enno Spillner Chief Financial Officer
Cord E. Dohrmann Chief Scientific Officer
Sector and Competitors
1st jan.Capitalization (M$)
EVOTEC SE11.67%5 024
IQVIA HOLDINGS INC.9.26%32 365
HANGZHOU TIGERMED CONSULTING CO.,LTD79.46%15 070
PRA HEALTH SCIENCES, INC.-0.14%7 120
SYNEOS HEALTH, INC.12.08%6 932
NOVAVAX, INC.2,477.89%6 427